sodium phenylbutyrate taurursodiol ALS
Selected indexed studies
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (N Engl J Med, 2020) [PMID:32877582]
- Sodium Phenylbutyrate-Taurursodiol for ALS. (N Engl J Med, 2020) [PMID:33264553]
- Sodium Phenylbutyrate-Taurursodiol for ALS. (N Engl J Med, 2020) [PMID:33264554]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Current State and Future Directions in the Therapy of ALS. (2023) pubmed
- Tofersen for SOD1 ALS. (2024) pubmed
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (2020) pubmed
- Sodium Phenylbutyrate-Taurursodiol for ALS. (2020) pubmed
- Sodium Phenylbutyrate-Taurursodiol for ALS. (2020) pubmed
- Sodium Phenylbutyrate-Taurursodiol for ALS. Reply. (2020) pubmed
- Real world experience with sodium phenylbutyrate-taurursodiol for ALS: Lessons learned from a failed drug. (2024) pubmed
- Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial. (2024) pubmed
- Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis. (2024) pubmed
- Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls. (2023) pubmed